Endonovo Therapeutics

Endonovo Therapeutics is a commercial-stage developer of non-invasive wearable medical devices delivering proprietary Electroceutical® Therapy for inflammatory conditions, cardiovascular diseases, and central nervous system disorders. The company's flagship product, SofPulse®, harnesses bioelectricity to restore electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing. Endonovo's Electroceutical® Therapy is FDA-Cleared for palliative treatment of pain and post-surgical edema, with CE Mark for wound healing promotion and pain/edema treatment. The company holds CMS National Coverage for chronic wound treatment. Current pipeline includes clinical-stage therapies targeting ischemic heart disease, acute concussions, post-concussion syndrome, traumatic brain injury (TBI), and multiple sclerosis. The technology platform operates through pulsed electromagnetic field (PEMF) delivery mechanisms designed as wearable, non-invasive systems. Endonovo is publicly traded on the OTCQB market (ticker: ENDV) and demonstrates commitment to evidence-based therapeutic development with regulatory-cleared and clinically-validated products.